Correction: Phase 1 study of the FcRH5×CD3 bispecific antibody cevostamab for relapsed or refractory multiple myeloma
-
By
-
Adam D. Cohen
-
Joshua Richter
-
Suzanne Trudel
-
Alexander Lesokhin
-
Jacob P. Laubach
-
Sheeba K. Thomas
-
Simon J. Harrison
-
Luciano J. Costa
-
Andrew Spencer
-
Rafael Fonseca
-
Peter A. Forsberg
-
Jesus G. Berdeja
-
Rayan Kaedbey
-
Nizar J. Bahlis
-
Paula Rodriguez-Otero
-
Maria-Victoria Mateos
-
Tulika Tyagi
-
Divya Samineni
-
Wenyu Liu
-
Rin Nakamura
-
Voleak Choeurng
-
Chihunt Wong
-
James Cooper
-
Amrita Krishnan
-
October 20, 2026
